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Objective. CD6 is an important regulator of T cell function that interacts with the ligands CD166 and CD318. To 
further clarify the significance of CD6 in rheumatoid arthritis (RA), we examined the effects of targeting CD6 in the 
mouse model of collagen- induced arthritis (CIA), using CD6- knockout (CD6- KO) mice and CD6- humanized mice that 
express human CD6 in lieu of mouse CD6 on their T cells.
Methods. We immunized wild- type (WT) and CD6 gene–KO mice with a collagen emulsion to induce CIA. For 
treatment studies using CD6- humanized mice, mice were immunized similarly and a mouse anti- human CD6 IgG 
(UMCD6) or control IgG was injected on days 7, 14, and 21. Joint tissues were evaluated for tissue damage, leukocyte 
infiltration, and local inflammatory cytokine production. Collagen- specific Th1, Th9, and Th17 responses and serum 
levels of collagen- specific IgG subclasses were also evaluated in WT and CD6- KO mice with CIA.
Results. The absence of CD6 reduced 1) collagen- specific Th9 and Th17, but not Th1 responses, 2) the levels of 
many proinflammatory joint cytokines, and 3) serum levels of collagen- reactive total IgG and IgG1, but not IgG2a and 
IgG3. Joint homogenate hemoglobin content was significantly reduced in CD6- KO mice with CIA compared to WT 
mice with CIA (P < 0.05) (reduced angiogenesis). Moreover, treating CD6- humanized mice with mouse anti- human 
CD6 monoclonal antibody was similarly effective in reducing joint inflammation in CIA.
Conclusion. Taken together, these data suggest that interaction of CD6 with its ligands is important for the 
perpetuation of CIA and other inflammatory arthritides that are T cell driven.
INTRODUCTION
CD6 is a 105–130- kd cell surface glycoprotein that is 
expressed by almost all mature T lymphocytes, many natural 
killer cells, and a small subset of B lymphocytes. Evidence 
of a role of CD6 in T cell activation includes the effects of 
anti- CD6 monoclonal antibodies (mAb) on the proliferation of 
freshly isolated T cells and recall responses of T cell clones 
(1,2), the influence of CD6 on T cell receptor–associated 
signaling events (2–6), altered activation and differentiation 
of T cells from CD6- knockout (CD6- KO) mice (7,8), and the 
effects of CD6 on thymic selection of developing T cells (7,9). 
Recent data also suggest that CD6 may be very important 
in T cell–driven autoimmune diseases both in humans and in 
animal models. Loci associated with CD6 affect susceptibility 
to multiple sclerosis (MS) (10) and Behçet’s syndrome, and the 
severity of psoriasis (11). Notably, an anti- CD6 mAb is effective 
in the treatment of psoriasis (12).
Although CD6 was one of the earliest “CD antigens” to be 
described, it is only recently that attention has refocused on the 
potential for CD6 as a treatment target in immune- mediated 
diseases. CD166, also known as activated leukocyte cell adhe-
sion molecule (ALCAM), was the first endogenous ligand of CD6 
to be identified (13), and is expressed on the surface of numer-
ous types of hematopoietic and nonhematopoietic cells, including 
activated lymphocytes and antigen- presenting cells (13). Recently, 
CD318, a cell surface molecule expressed on various mesenchy-
mal and epithelial cell types (but not on mature lymphoid or mye-
loid cells), was also shown to be a ligand of CD6 (14). CD166 
and CD318 bind to different domains of CD6 and appear to 
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have distinct functions in autoimmune conditions. For instance, 
CD166- KO mice developed worse experimental autoimmune 
encephalomyelitis (EAE) (15), while CD318- KO mice, similar to 
CD6- KO mice, were protected against EAE (14). Interestingly, 
CD6, CD166, and CD318 are all strongly expressed in the joints 
of patients with rheumatoid arthritis (RA) (14,16–18).
In RA, both CD166 and CD318 are expressed by fibroblast- 
like synoviocytes (FLS), and these ligands participate in T cell 
binding to FLS (14,18,19). FLS also shed some of their surface 
CD318 into RA synovial fluid, and we have shown that soluble 
CD318 (sCD318) is chemotactic for T cells at concentrations 
equivalent to the gradient between RA synovial fluid and serum 
(14). These findings imply a role for the CD6–CD6 ligand axis in the 
pathogenesis of RA. To test the potential effectiveness of CD6- 
targeted therapeutics in the treatment of inflammatory arthritis, we 
used 2 mouse models of collagen- induced arthritis (CIA): genet-
ically altered mice that lack CD6, and mice in which human CD6 
has been substituted for mouse CD6 to allow in vivo testing of 
anti- human CD6 mAb.
MATERIALS AND METHODS
Animals. Wild- type (WT) mice, CD6- KO mice, and CD6- 
humanized mice (on a DBA/1J background) (8) were maintained 
under pathogen- free conditions in the animal facility of the Lerner 
Research Institute, Cleveland Clinic. All procedures involving mice 
were approved by the Institutional Animal Care and Use Committee 
(IACUC) of Cleveland Clinic, and all were done in accordance with 
the US Department of Health and Human Services Guide for the 
Care and Use of Laboratory Animals and institutional guidelines.
Induction of murine CIA. We immunized age- and sex- 
matched WT and CD6- KO mice with a collagen emulsion to 
induce CIA as previously described (20). Mice were immunized at 
the base of the tail with bovine type II collagen (Chondrex) emul-
sified (2 mg/ml) at 1: 1 ratio in a custom- made Freund’s complete 
adjuvant containing 4 mg/ml M tuberculosis (BD Biosciences) in a 
total volume of 50 μl.
Clinical assessment of CIA. We used a scoring system 
identical to that used in previously published studies of CIA (21). 
Briefly, each joint was inspected and scored for the severity of swell-
ing on a scale of 0–3, where 0 = normal appearance, 1 = mild, 
2 = moderate, and 3 = severe, yielding a maximum score of 12 for 
each mouse. Swollen digits were noted, but paws were only con-
sidered arthritic when the entire paw was inflamed for 2 consecutive 
days. The day of onset of arthritis was recorded for each mouse. 
During the chronic phase of the arthritis, paws and digits were 
inspected for distortion and manipulated to identify loss of flexion 
(ankylosis). Severity scores were obtained by summing the inflam-
mation, distortion, and ankylosis scores. Scores for each mouse 
were used to derive a mean arthritis severity score for the groups at 
each time point examined. Development of CIA in the CD6 gene–
KO mice and WT control mice was monitored by visual scoring 
every other day from 21 days after immunization until day 28.
For treatment studies using CD6- humanized mice, we immu-
nized mice as described above, and mice were randomly sepa-
rated into 2 groups 7 days after immunization. One group was 
injected intraperitoneally (IP) with 0.4 mg of a mouse anti- human 
CD6 IgG (UMCD6) (22) on days 7, 14, and 21, and the other group 
received the same amount of purified mouse IgG (Jackson Immu-
noResearch) as a control. Mice were then monitored, and clinical 
scores were recorded 3 times a week in a blinded manner. At 
the end of the experiments, mice were euthanized, and peripheral 
blood lymphocytes, splenocytes, and draining lymph nodes were 
analyzed for percentages of CD4+ and CD6+ T cells. Splenocytes 
were used to carry out antigen- specific Th1, Th9, and Th17 recall 
assays, and paws/joints were analyzed using histologic and his-
tochemical assays.
Histologic analysis of mouse joint tissue. Some of 
the mouse ankles were embedded in OCT for sectioning. Briefly, 
serial synovial tissue sections (5–8 μm) were cut frozen and stored 
at –80°C for future hematoxylin and eosin and immunofluores-
cence staining. Frozen slides were allowed to thaw and dry at 
room temperature and subsequently fixed in acetone for 10 min-
utes at 4°C. For immunohistochemistry, tissue slides were blocked 
with 5% donkey serum and 20% fetal bovine serum (FBS) in phos-
phate buffered saline (PBS) at 37°C for 1 hour. After blocking, flu-
orescein isothiocyanate (FITC)–labeled anti- mouse CD3 antibody 
was added and incubated for 2 hours at room temperature. FITC- 
tagged mouse IgG was used as a control. DAPI was used at a 
1:5,000 dilution in PBS for 5 minutes. Slides were then mounted 
in Fluoromount- G and visualized under a fluorescence microscope.
Mouse joint homogenate preparation and multiplex 
assays. Mice were euthanized and joints and sera were collected. 
Front paws and hind joints were used in the study. Joints were 
removed directly below the hairline and snap- frozen in liquid nitro-
gen. All joints were stored at −80°C until processed. Each joint 
was thawed on ice and quickly homogenized on ice in 1–2 ml 
PBS containing a tablet of proteinase inhibitors (10 ml PBS/tablet; 
Boehringer Mannheim). Homogenized tissues were centrifuged at 
2,000g at 4°C for 10 minutes, and then filtered, aliquotted, and 
stored at −80°C until analyzed by enzyme- linked immunosorbent 
assay (ELISA). Protein concentrations were determined using a 
BCA Protein Assay kit (ThermoFisher), and the concentrations of 
32 different mouse cytokines/chemokines in the homogenates 
were measured by a multiplex assay (Eve Technologies) and nor-
malized against the total protein of each tissue lysate.
ELISA for murine CD318. We used a direct ELISA to mea-
sure the levels of murine CDCP1 (CD318) in mouse joint tissue 
homogenates (R&D Systems).
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Serum collagen- specific IgG measurement. To mea-
sure type II collagen–specific IgG levels in the serum, blood 
samples were collected from the tail vein of each mouse and 
analyzed by ELISA. Briefly, sera were diluted (1:1,000) and then 
incubated in wells of a 96- well ELISA plate coated with 10 μg/ml 
purified type II collagen. After washing, horseradish peroxidase 
(HRP)–conjugated rabbit anti- mouse IgG (1:4,000; Southern 
Biotechnology) was added into each well and the levels of type II 
collagen–specific IgGs in the sera were determined by measur-
ing optical density (OD) at 450 nm after color development using 
a 3,3′,5,5′- tetramethylbenzidine (TMB) substrate (ThermoFisher 
Scientific). To determine the levels of different type II collagen–
specific IgG subclasses, similar ELISAs were performed with 
IgGs specific for mouse IgG1, IgG2a, IgG2b, and IgG3 (Sigma- 
Aldrich) as the detecting antibodies. All samples were run in 
duplicate.
Type II collagen–specific Th1, Th9, and Th17 cell 
recall assays. Spleens were collected and processed from 
WT and CD6- KO mice with CIA, or from CD6- humanized mice 
treated with UMCD6 or control mouse IgG after CIA induction. 
Splenocytes (0.4 × 106) were incubated with or without 10 
μg/ml type II collagen or the same concentration of an irrele-
vant peptide (ovalbumin [OVA] 323–339) in RPMI 1640 com-
plete medium with 10% (volume/volume) FBS in each well of a 
96- well plate. After 72 hours, interferon- γ (IFNγ), interleukin- 9 
(IL- 9), and IL- 17A levels in the culture supernatants were mea-
sured by ELISA following standard protocols. Briefly, ELISA 
plates were coated with 4 μg/ml anti- mouse IFNγ IgG (BioLeg-
end), anti- mouse IL- 9 IgG (BD Biosciences), or anti- mouse IL- 
17A IgG (BioLegend) overnight and then blocked with 1 mg/
ml bovine serum albumin. Next, culture supernatants were 
added to each well and incubated for 2 hours. After washing, 
1 μg/ml biotinylated anti- mouse IFNγ, IL- 9, or IL- 17A IgG was 
added into each well and incubated for an additional 1 hour. 
The plates were then developed after incubation with streptavi-
din–HRP (1:4,000; BioLegend) and TMB substrate. The con-
centrations of IFNγ, IL- 9, and IL- 17A in the supernatants were 
calculated by measuring OD at 450 nm. All samples were run 
in duplicate.
Hemoglobin (Hgb) measurement on hind joint 
homogenates. For measurement of Hgb concentration, a reflec-
tion of vascularity of the tissue, mouse joints were homogenized 
as previously described. Hgb levels were measured by adding 25 
μl of homogenate mixed with 25 μl of TMB reagent to 96- well 
plates. Samples were incubated for 5 minutes at room tempera-
ture, and absorbance was measured using a Microplate Manager 
ELISA reader (BioTek Instruments) at 450 nm. Hgb concentrations 
were determined by comparison with a standard curve. Values 
were normalized by dividing the Hgb concentration by the amount 
of total protein in the homogenate.
Statistical analysis. Experiments were repeated at least 
twice. To determine whether significant differences existed 
between groups, clinical scores were analyzed using analysis of 
variance, and other results were compared using Student’s t- test. 
P values less than 0.05 were considered significant. Data are 
shown as the mean ± SEM except where indicated otherwise.
RESULTS
Reduced clinical CIA severity in CD6- KO mice. We 
immunized age- and sex- matched CD6- KO mice and WT con-
trol mice with collagen emulsion to induce CIA. Beginning on day 
21 after immunization, CIA clinical scores were recorded by an 
investigator who was blinded with regard to group until day 28, 
when the WT mice developed severe arthritis and had to be euth-
anized according to the IACUC- approved study protocol. CIA 
severity was scored in each joint (front and hind) from WT and 
CD6- KO mice. A reduction in CIA severity in the CD6- KO mice 
was evident on day 23 and later (Figure 1), as differences were 
Figure 1. Reduction in the severity of collagen- induced arthritis 
(CIA) in CD6- knockout (CD6- KO) mice compared to wild- type 
(WT) mice. Top, Clinical score of CIA severity in WT and CD6- KO 
mice. CIA severity was measured in each paw and ankle (front 
and hind joints). A total reduction in CIA severity in the CD6- KO 
mice was evident on day 23 after induction of CIA and later. Values 
are the mean ± SEM (n = 14 mice per group). Bottom, Synovial 
inflammatory response on day 28 in a CD6- KO mouse (left) and 
a WT mouse (right). WT mice had a robust synovial inflammatory 
response that was not evident in the CD6- KO mice. Results are 
representative of 14 mice per group.
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significant at all time points except early on day 21. WT mice had 
a robust inflammatory response to collagen on day 28 that was 
not evident in the CD6- KO mice. This finding indicates that CD6 
deficiency partially protected mice against CIA.
Attenuated clinical CIA severity in CD6- humanized 
mice treated with UMCD6. To further assess CD6 as a poten-
tial target in the treatment of CIA, we induced arthritis in CD6- 
humanized DBA/1 mice and randomly divided these mice into 2 
groups. The first group was injected IP with a mouse anti- human 
CD6 mAb (UMCD6), and a second group was injected similarly 
with purified mouse IgG, on days 7, 14, and 21. To monitor CIA 
development, clinical scores were recorded in a blinded manner 
from day 21 to day 35. UMCD6 effectively mitigated the severity 
of joint swelling after day 21 (Figure 2). Moreover, mice treated 
with IgG had demonstrable synovial lymphocyte staining (fluo-
rescent green cells) on day 35 that was absent in the UMCD6- 
treated mice.
Reduced collagen- specific Th1/Th9/Th17 responses 
in CD6- humanized mice treated with UMCD6. Collagen- 
specific Th1//Th9/Th17 recall assays using splenocytes from 
the UMCD6- treated CD6- humanized mice 35 days after CIA 
induction were used to evaluate pathogenic T cell responses. 
These experiments showed that levels of IFNγ, IL- 9, and IL- 
17A in the recall assays were significantly reduced in UMCD6- 
treated mice with CIA compared to IgG- treated control mice 
with CIA (Figure  3). This finding demonstrates that UMCD6 
profoundly impaired the pathogenic T cell responses in the 
CD6- humanized mice after CIA induction, which could be 
a mechanism underlying the reduced clinical severity of CIA 
observed in the UMCD6- treated mice.
Reduced collagen- specific Th9 and Th17 responses 
in CD6- KO mice following CIA induction. We collected sple-
nocytes from WT and CD6- KO mice with CIA on day 28 to assess 
collagen- specific Th1, Th9, and Th17 responses. The correspond-
ing measurements of IFNγ, IL- 9, and IL- 17A levels in the culture 
supernatants from recall assays indicated that collagen- specific 
Th9 and Th17 responses in CD6- KO mice were significantly 
reduced compared to those in WT mice. Although CD6- KO mice 
tended to also exhibit reduced collagen- specific Th1 responses, 
this difference was not significant (Figure 3).
Reduced levels of collagen- specific total IgG and 
IgG1, but not IgG2a and IgG3, in CD6- KO mice. Pre-
vious studies have implicated collagen- specific IgGs in the 
pathogenesis of CIA. Therefore, we used ELISAs to measure 
the levels of collagen- specific total IgG and collagen- specific 
IgG subclasses in sera collected on day 28. Notably, levels of 
collagen- specific IgGs were significantly reduced in sera from 
CD6- KO mice compared to WT mice. In the IgG subclass anal-
yses, we observed reduced levels of collagen- specific IgG1 in 
CD6- KO mice compared to WT mice (Figure 4), while the lev-
els of IgG2a or IgG3 were not significantly affected (data not 
shown).
Altered cytokine production profiles in the joints of 
CD6- KO mice after CIA development. Using a cytokine mul-
tiplex assay, the levels of 32 inflammatory cytokines from homoge-
nates of collected paw and ankle joint tissues were measured 
and normalized against the concentrations of total proteins. The 
paws and hind joints of CD6- KO mice exhibited attenuated tissue 
damage and leukocyte infiltration, consistent with the significantly 
reduced clinical scores in CD6- KO mice (Figure 5). In addition, 
the cytokine multiplex assays revealed that the levels of eotaxin, 
granulocyte colony- stimulating factor, IFNγ, IL- 1β, IL- 2, IL- 5, IL- 9, 
IL- 12 (p70), IL- 17, IFNγ- inducible 10- kd protein, keratinocyte 
Figure  2. Reduction in the severity of collagen- induced arthritis 
(CIA) in CD6- humanized mice treated with a mouse anti- human CD6 
IgG (UMCD6). Top, Clinical score of CIA severity in CD6- humanized 
mice treated with IgG and CD6- humanized mice treated with 
UMCD6. CIA severity was measured in each paw and ankle (front 
and hind joints) from CD6- humanized mice with CIA that had been 
treated with either human IgG or UMCD6 antibody on days 7, 14, 
and 21. A total reduction in CIA severity in the UMCD6- treated mice 
was evident on day 28 after induction of CIA and later. Values are 
the mean ± SEM (n = 14 mice per group). Bottom, Synovial CD3+ 
lymphocyte staining on day 35 in a mouse treated with IgG (left) 
and a mouse treated with UMCD6 (right). Mice treated with IgG had 
demonstrable synovial CD3+ lymphocyte (L) staining (fluorescent 
green cells; arrows) that was not evident in mice treated with 
UMCD6. Results are representative of 14 mice per group.
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chemoattractant, monocyte chemotactic protein 1, macrophage 
colony- stimulating factor, macrophage inflammatory protein 1α 
(MIP- 1α), MIP- 2, RANTES, tumor necrosis factor, and vascular 
endothelial growth factor (VEGF) were significantly lower in the 
CD6- KO group compared to the WT group. In contrast, the levels 
of granulocyte–macrophage colony- stimulating factor, IL- 1α, IL- 3, 
IL- 4, IL- 6, IL- 7, IL- 10, IL- 12 (p40), IL- 15, leukemia inhibitory factor, 
lipopolysaccharide- induced CXC chemokine, monokine induced 
by IFNγ, and MIP- 1β were comparable between the two groups 
of mice (Figure 5).
UMCD6 modulation of CD6 expression on CD4+ T 
cells without depletion of this T cell population in 
treated mice. On day 35 after CIA induction, we obtained 
blood and draining lymph nodes from CD6- humanized mice 
treated with UMCD6 or with mouse IgG and analyzed the 
Figure 3. Reduced T cell cytokine production in response to collagen due to blocking or absence of CD6 in mice. Top, Reactivity to collagen 
in vitro in splenocytes from mice with collagen- induced arthritis (CIA) treated with IgG, but not mice with CIA treated with a mouse anti- human 
CD6 IgG (UMCD6), in Th1//Th17/Th9 recall assays. Secretion of interferon- γ (IFNγ), interleukin- 17A (IL- 17A), and IL- 9 was significantly lower in 
UMCD6- treated mice. Controls included no antigen (w/o) and an irrelevant antigen (ovalbumin [OVA] 323–329 peptide). Bottom, Significantly 
reduced collagen- specific Th17 and Th9, but not Th1, responses in splenocytes from CD6- knockout (CD6- KO) mice compared to wild- type 
(WT) mice after the induction of CIA. For each cytokine tested, the enzyme- linked immunosorbent assays have sensitivities in the picogram 
range. Bars show the mean ± SEM (n = 14 mice per group).
Figure 4. Reduced total serum levels of IgG and IgG1 against type II collagen in CD6- knockout (CD6- KO) mice with collagen- induced arthritis 
(CIA). Total serum levels of IgG anti–type II collagen (anti- CII) and IgG1 anti- CII in wild- type (WT) mice with CIA and CD6- KO mice with CIA 
were measured by enzyme- linked immunosorbent assay. Symbols represent individual mice; horizontal lines and bars show the mean ± SEM.
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percentages of CD4+ T cells and their CD6 expression lev-
els by flow cytometry. The UMCD6- treated and mock- treated 
samples contained similar percentages of total CD4+ T cells. 
However, the percentage of CD4+CD6+ T cells was signifi-
cantly reduced in the UMCD6- treated mice, and this reduc-
tion was even more profound in the draining lymph nodes 
than in the peripheral blood (Supplementary Figure 1, avail-
able on the Arthritis & Rheumatology website at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41288/ abstract). A further 
analysis of CD4+ T cells from UMCD6- treated mice revealed 
that most T cells did not express detectable levels of CD6. Thus, 
UMCD6 treatment modulated the expression of CD6 on CD4+ T 
cells rather than depleting these T cells in CD6- humanized mice 
with CIA.
Reduced Hgb levels in the joint tissue homogenates 
of CD6- KO mice with CIA. Measurement of Hgb in joint tissue 
homogenates revealed a significant reduction in Hgb content in 
CD6- KO mice with CIA compared to WT control mice with CIA, 
signifying attenuated angiogenic activity in the CD6- KO mice (Sup-
plementary Figure 2, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41288/ 
abstract). Reductions in Hgb content were not observed in CD6- 
humanized mice with CIA treated with UMCD6 compared to con-
trol mice (Supplementary Figure 2).
DISCUSSION
CD6 is an important regulator of T cell function that medi-
ates the interactions of T cells with a wide variety of other cell 
types through engagement of its ligands CD166 and CD318. We 
previously examined CD318 expression in synovial tissue and 
sCD318 concentrations in the synovial fluid of RA patients and 
demonstrated a potential role for CD318 in the recruitment 
and retention of T cells in the RA joints. To further clarify the signif-
icance of CD6 in RA, in this study we examined the effects of tar-
geting CD6 in the mouse model of CIA using CD6- KO mice and 
CD6- humanized mice that express human CD6 in lieu of mouse 
CD6 on their T cells. Using these models, we analyzed the joints 
of the ankles and paws for tissue damage, leukocyte infiltration, 
and local inflammatory cytokine production. We also compared 
collagen- specific Th1, Th9, and Th17 responses and serum levels of 
collagen- specific IgG subclasses and used cytokine multiplex assays 
to measure the levels of 32 cytokines in homogenates of joint tissues.
We found that CD6- KO mice had significantly lower clini-
cal arthritis scores than WT mice, suggesting that CD6 acts to 
Figure 5. Cytokine panels from joint homogenates of CD6- knockout (CD6- KO) mice with collagen- induced arthritis (CIA) and wild-type (WT) 
mice with CIA. Joints from WT mice and CD6- KO mice were homogenized and protein concentrations were measured. A cytokine multiplex 
assay was used to measure the levels of 32 cytokines in homogenates of each of the paw and ankle joint tissues. Cytokine levels were normalized 
to protein concentration for each joint tissue homogenate (pg cytokine/mg protein). The levels of many proinflammatory cytokines were reduced 
in CD6- KO mice with CIA compared to WT mice with CIA. P values are shown for each cytokine. Significant P values are shown in red. Symbols 
represent individual mouse hind joints; bars show the mean ± SEM. IL- 4 = interleukin- 4; G- CSF = granulocyte colony- stimulating factor; 
GM- CSF = granulocyte–macrophage colony- stimulating factor; IFNγ = interferon- γ; M- CSF = macrophage colony- stimulating factor; 
MIG = monokine induced by interferon- γ; MIP- 1α = macrophage inflammatory protein 1α; TNF = tumor necrosis factor; VEGF = vascular 
endothelial growth factor; IP- 10 = interferon- γ–inducible 10- kd protein; KC = keratinocyte chemoattractant; LIF = leukemia inhibitory factor; 
LIX = lipopolysaccharide- induced CXC chemokine; MCP- 1 = monocyte chemotactic protein 1.
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attenuate the severity of joint inflammation in CIA. The absence of 
CD6 reduced 1) collagen- specific Th9 and Th17 responses, 2) the 
levels of many proinflammatory joint cytokines and chemokines, 
3) serum levels of collagen- reactive total IgG and IgG1, but not 
IgG2a and IgG3, and 4) synovial angiogenesis in CD6- KO mice. 
Recall assays using collagen, or OVA 323–339 peptide as an irrel-
evant antigen, showed significant reductions in the production of 
IFNγ, IL- 17, and IL- 9 in mice with CIA when CD6 was targeted. 
These findings are consistent with our previously published data 
showing that T cells from CD6- KO mice had enhanced prolifera-
tion, but diminished Th1 and Th17 cell differentiation in response 
to anti- CD28 and anti- CD3 antibodies (8). Moreover, treating 
CD6- humanized mice with a mouse anti- human CD6 mAb was 
similarly effective in reducing joint inflammation in CIA. The reduc-
tion in inflammatory cytokine levels occurred without significant 
depletion of T cells and was even more profound in UMCD6- 
treated mice than in CD6- KO mice. Furthermore, we showed that 
there were more synovial CD3+ lymphocytes in the tissue sec-
tions prepared from IgG- treated mice with CIA than in those from 
UMCD6- treated mice with CIA, likely due to an overall reduction 
in T cell recruitment to inflamed synovium in response to therapy.
The previously identified ligand of CD6 is ALCAM (CD166), 
a member of the immunoglobulin gene superfamily that is widely 
expressed on cells of the immune system, including activated T 
and B lymphocytes, and on many types of mesenchymal, epi-
thelial, and endothelial cells in various organs and tissues. Indi-
cations that a second ligand of CD6 might exist arose initially 
from functional studies in which T cell adhesion to keratinocytes 
and synovial fibroblasts was found to be dependent on CD6 but 
not on CD166 (19). Moreover, these interactions involved a CD6 
ligand whose expression was increased by IFNγ, a cytokine that 
does not up- regulate CD166 (17,19). Subsequently, an mAb was 
generated that identified a 130- kd molecule that also bound to a 
CD6–Ig fusion protein (18); we recently identified this CD6 ligand 
as CD318 (14). CD318 is expressed by a variety of tissue cell 
types with which T cells interact in organ- targeted autoimmune 
diseases, but it is not expressed on mature cells of the immune 
system such as lymphocytes and myeloid cells (2,18). CD166 and 
CD318 bind to distinct domains of CD6, and it appears possible 
that CD6 can bind both ligands concurrently (14).
Recent work suggests that the appearance of sCD318 in 
synovial fluid is a potential biomarker for RA and closely related 
conditions, and also highlights the importance of T cell interac-
tions with FLS and with molecules shed from the FLS surface 
(14). UMCD6 treatment of mice with CIA reduced lesional levels 
of sCD318, possibly through down- regulation of the expression of 
proinflammatory cytokines such as IFNγ, which in turn up- regulate 
CD318 expression. This effect on sCD318 levels was not observed 
in CD6- KO mice (Supplementary Figure 2). On the other hand, 
CD6- KO mice with CIA showed reduced synovial angiogenesis 
compared to WT mice, but this effect was not seen in UMCD6- 
treated CD6- humanized mice. These differences suggest that, 
notwithstanding similar effects on T effector cell subset differen-
tiation, the genetic absence of CD6 versus the use of anti- CD6 
antibody impacts CIA by mechanisms that differ in subtle ways 
at the target organ, the synovium. Elucidation of the mechanis-
tic basis for these differences will require additional experimental 
approaches, possibly including tissue- specific manipulation of the 
expression of CD6 ligands.
While no animal model is an exact replica of RA, the 
murine model of CIA has proven to be very useful in studies of the 
pathogenesis of RA (20). CIA is typically induced in mice or rats 
by immunization with heterologous type II collagen, the principal 
type of collagen that is present in articular cartilage. In susceptible 
strains of rodents, an autoreactive response against type II colla-
gen is induced, leading to synovitis and joint destruction over an 
interval of several weeks. As in human RA, multiple immune and 
inflammatory events and pathways are involved, including auto-
reactive Th1 and Th17 T cells, autoantibodies, proinflammatory 
cytokines, and activated, tissue- destructive synovial cells (20). 
Moreover, synovial enrichment of Th9 cells shows a positive cor-
relation with disease activity in RA, and synovial IL- 9 prolongs the 
survival of neutrophils, increases their matrix metalloproteinase 9 
production, and facilitates Th17 cell differentiation (23).
Since Hgb levels have been correlated with joint inflamma-
tion and up- regulated angiogenesis in RA, and in animal models 
of RA (24–26), we examined Hgb levels as a measure of tis-
sue vascularity in the joint tissue homogenates of the WT and 
CD6- KO mice with CIA. Our data show significant reductions 
in joint Hgb levels in the CD6- KO mice with CIA compared to 
WT mice with CIA, and this corresponds to reductions in several 
key angiogenic factors that we measured in our cytokine array, 
including VEGF.
In studies using CD6- KO mice, Orta- Mascaro and colleagues 
observed heightened autoimmunity and exacerbated disease 
in the CIA model (7). These experiments were performed in the 
C57BL/6 mouse strain in which the severity of CIA is modest. In 
view of the apparent contradiction between our previous findings 
in EAE and these results in CIA, we performed experiments to 
assess the role of CD6 in CIA, using the DBA mouse strain, in 
which CIA is considerably more severe than in C57BL/6 mice. We 
found that, as in EAE, the absence of CD6 is indeed protective 
in CIA in the DBA strain, and that treatment with anti- CD6 has 
therapeutic effects.
CD6- humanized mice provide a useful preclinical in 
vivo model for demonstrating the effectiveness of anti- CD6 anti-
bodies in the treatment of autoimmune conditions. UMCD6 sig-
nificantly reduced inflammatory responses in the target organs 
of CIA, EAE, and experimental autoimmune uveitis in these mice 
(2,27). Further, UMCD6 is an effective agent in suppressing 
differentiation of autoreactive lymphocytes into pathogenic, 
cytokine- producing Th1 and Th17 cells. Similar alteration in 
the differentiation of Th1 and Th17 cells occurs in CD6-KO and 
CD318- KO mice (2).
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Although there is some evidence that CD6 can augment sig-
nal transduction through the T cell receptor complex (3,28), our 
recent studies in CD6- deficient mice indicate that CD6 attenuates 
the early stages of T cell activation and also enhances differentia-
tion of Th1 and Th17 CD4 effector cells (8). These Th1 and Th17 
CD4+ effector cells then drive autoimmune disease(s), including 
RA. Precisely how CD6 signals upon engagement of its natural 
ligands is unknown, but the cytoplasmic region of CD6 can be 
phosphorylated by multiple kinases (29). Many details of how 
CD6 participates in T cell signaling remain unclear, including the 
positioning of CD6 with respect to the “immunological synapse” 
formed through contact of the T cell with antigen- presenting cells. 
Thus, the role of CD6 in fomenting organ- targeted autoimmu-
nity may specifically reflect CD6 interaction with CD318, which is 
expressed on key tissue cells in these diseases including neurons 
and endothelial cells in the brain, synovial fibroblasts in the joint, 
and keratinocytes in the skin (2,18). In the 1980s, an IgM anti- CD6 
was tested in clinical trials on MS (30) and allograft rejection (31), 
but the small size and uncontrolled design of those studies pre-
cluded determination of therapeutic efficacy. More recently, an 
anti- CD6 mAb termed itolizumab has been extensively studied in 
humans with psoriasis and was demonstrated to be of significant 
clinical benefit, leading to approval for treatment of psoriasis in 
India (12).
UMCD6 is an mAb that has very high affinity for CD6 (16) 
without depleting T cells in CD6- humanized mice. UMCD6 
instead appears to strip CD6 from the T cell surface, likely through 
internalization. If anti- CD6 mAb were similarly non–lymphocyte- 
depleting in humans, host defenses against infection might be 
relatively well preserved compared to other immunosuppres-
sive strategies, and could lead to a safety advantage for CD6- 
directed mAb (2,14). The findings of the present study, taken 
together with what is already known about the role of CD6 in 
other mouse models of autoimmune diseases, strongly suggest 
that CD6 is required for the development and perpetuation of 
inflammatory arthritis and other autoimmune disorders that are T 
cell driven, and that attenuation of such disorders is achievable 
through targeting of CD6.
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Errata
DOI 10.1002/art.41494 
In the article by Gilis et  al in the December 2019 issue of Arthritis and Rheumatology (Deletion of Mucosa- 
Associated Lymphoid Tissue Lymphoma Translocation Protein 1 in Mouse T Cells Protects Against Development 
of Autoimmune Arthritis but Leads to Spontaneous Osteoporosis [pages 2005–2015]), a statement regarding 
shared senior authorship by two of the authors was inadvertently omitted from the title- page footnotes. The state-
ment that should have appeared was “Drs. Beyaert and Elewaut contributed equally to this work.”
DOI 10.1002/art.41495 
In the article by Kwon et al in the May 2020 issue of Arthritis and Rheumatology (Negative Regulation of Oste-
oclast Commitment by Intracellular Protein Phosphatase Magnesium- Dependent 1A [pages 750–760]), there 
was an error in the grant number shown for one of the grants that supported the study. The paragraph in the 
title- page footnotes should have read “Supported by grants from the Basic Science and Engineering Research 
Program (2018R1A2B2001867) and the National Research Foundation of Korea Medical Research Council 
(funded by the Korean government’s Ministry of Science, ICT, and Future Planning) to Drs. Chang and Y.- G. Kim 
(2018R1A5A2020732 and NRF- 2019- R1F1A1059736, respectively).”
We regret the errors.
